CLAIMS

1. Use of an anti-CGRP antibody in the manufacture of a medicament for treating migraine or headache in a patient in the need of immediate relief of migraine or headache symptoms, or for preventing migraine or headache in a patient in need of immediate preventative treatment of migraine or headache,

wherein said anti-CGRP antibody is to be administered via intravenous infusion in a dosage of 100 or 300 mg of said anti-CGRP antibody, and

wherein said anti-CGRP antibody comprises the light chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 224; SEQ ID NO: 226; and SEQ ID NO: 228, respectively and heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 204; SEQ ID NO: 206; and SEQ ID NO: 208, respectively, and

wherein said anti-CGRP antibody is to be administered to a patient who patient exhibits at least one headache and/or migraine symptom at the time of administration.

2. The use according to claim 1, wherein said at least one headache and/or migraine symptom comprises one or more of pain, nausea, photophobia, or phonophobia.

3. The use according to claim 2, wherein said pain is head pain.

4. The use according to any one of claims 1-3, wherein the most bothersome symptom is alleviated after said administration, such as within the first day after administration, within 12 hours after administration, within 6 hours after administration within 5 hours after administration, within 4 hours after administration, within 3 hours after administration, within 2 hours after administration, or within 1 hour of after administration, within 30 minutes after administration, or such as between 1-6 hours after administration.

5. The use according to any one of claims 1-4, wherein said patient no longer has a migraine after said administration, such as within the first day after administration, within 12 hours after administration, within 6 hours after administration within 5 hours after administration, within 4 hours after administration, within 3 hours after administration, within 2 hours after administration, or within 1 hour of after administration, within 30 minutes after administration, or such as between 1-6 hours after administration.

6. The use according to any one of the foregoing claims, wherein said anti-CGRP antibody comprises the variable light chain polypeptide of SEQ ID NO: 222.

7. The use according to any one of the foregoing claims, wherein said anti-CGRP antibody comprises the variable heavy chain polypeptide of SEQ ID NO: 202.

8. The use according to any one of the foregoing claims, wherein said anti-CGRP antibody comprises the variable light chain polypeptide of SEQ ID NO: 222 and the variable heavy chain polypeptide of SEQ ID NO: 202.

9. The use according to any one of the foregoing claims, wherein said anti-CGRP antibody comprises the light chain polypeptide of SEQ ID NO: 221.

10. The use according to any one of the foregoing claims, wherein said anti-CGRP antibody comprises the heavy chain polypeptide of SEQ ID NO: 201 or SEQ ID NO: 566.

11. The use according to any one of the foregoing claims, wherein said anti-CGRP antibody comprises the light chain polypeptide of SEQ ID NO: 221 and the heavy chain polypeptide of SEQ ID NO: 201 or SEQ ID NO: 566.